Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.

ABSTRACT:

Objective

Intravenous methylprednisolone is the standard treatment for a multiple sclerosis relapse; however, this fails to improve symptoms in up to one quarter of patients. Immunoadsorption is an accepted treatment for refractory relapses, but prospective comparator-controlled studies are missing.

Methods

In this observational study, patients with steroid-refractory acute multiple sclerosis relapses receiving either six courses of tryptophan-immunoadsorption or double-dose methylprednisolone therapy were analysed. Outcomes were evaluated at discharge and three months later. Immune profiling of blood lymphocytes and proteomic analysis were performed by multi-parameter flow cytometry and Olink analysis, respectively (NCT04450030).

Results

42 patients were enrolled (me

SUBMITTER: Pfeuffer S 

PROVIDER: S-EPMC9450381 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature